Mutual of America Capital Management LLC Has $1.82 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Mutual of America Capital Management LLC lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,718 shares of the medical research company’s stock after selling 138 shares during the period. Mutual of America Capital Management LLC’s holdings in Charles River Laboratories International were worth $1,820,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRL. VisionPoint Advisory Group LLC increased its holdings in shares of Charles River Laboratories International by 45.1% in the 4th quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 65 shares during the period. Brown Brothers Harriman & Co. increased its holdings in shares of Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $62,000. Bruce G. Allen Investments LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $70,000. Finally, Concord Wealth Partners increased its holdings in shares of Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 203 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 2.5 %

Shares of Charles River Laboratories International stock opened at $216.19 on Monday. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The stock has a market capitalization of $11.14 billion, a P/E ratio of 25.43, a PEG ratio of 2.05 and a beta of 1.38. The stock has a 50 day moving average price of $214.47 and a two-hundred day moving average price of $230.63. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. Equities analysts expect that Charles River Laboratories International, Inc. will post 11 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on CRL. Robert W. Baird lowered their price target on Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating for the company in a research note on Wednesday, July 10th. Mizuho began coverage on Charles River Laboratories International in a research note on Friday, June 7th. They issued a “neutral” rating and a $235.00 price target for the company. Barclays began coverage on Charles River Laboratories International in a research note on Friday, June 28th. They issued an “equal weight” rating and a $230.00 price target for the company. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Finally, TD Cowen lowered their price target on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research note on Monday, May 13th. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Charles River Laboratories International currently has an average rating of “Hold” and a consensus price target of $252.29.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the transaction, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).